Compare · SMLR vs TMDX
SMLR vs TMDX
Side-by-side comparison of Semler Scientific Inc. (SMLR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SMLR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.41B, about 7.2x SMLR ($470.7M).
- Over the past year, SMLR is down 37.1% and TMDX is up 7.7% - TMDX leads by 44.8 points.
- TMDX has hit the wire 6 times in the past 4 weeks while SMLR has been quiet.
- TMDX has more recent analyst coverage (17 ratings vs 6 for SMLR).
- Company
- Semler Scientific Inc.
- TransMedics Group Inc.
- Price
- $20.34-5.02%
- $98.98+0.43%
- Market cap
- $470.7M
- $3.41B
- 1M return
- +16.67%
- -0.40%
- 1Y return
- -37.13%
- +7.67%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 0
- 6
- Recent ratings
- 6
- 17
Semler Scientific Inc.
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest SMLR
- SEC Form SCHEDULE 13G filed by Semler Scientific Inc.
- SEC Form 15-12G filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
Latest TMDX
- TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
- The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
- TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
- TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
- SEC Form DEFA14A filed by TransMedics Group Inc.
- SEC Form DEF 14A filed by TransMedics Group Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.
- SEC Form 3 filed by new insider Forsyth Matthew S.
- Director Lovell Stephanie sold $178,497 worth of shares (1,193 units at $149.62), decreasing direct ownership by 29% to 2,866 units (SEC Form 4)
- Director Weill David exercised 3,571 shares at a strike of $14.20 and sold $524,294 worth of shares (3,571 units at $146.82) (SEC Form 4)